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OpenLow free T3 levels are related to early mortality
in patients with decompensated cirrhosis and acute-on
chronic liver failurecantly higher sequential-organ-failure-assessment (SOFA) (six
[5–8] vs. ﬁve [4–7.25], p = 0.023). Patients with low FT3 had a
worse outcome as it is shown by the Kaplan Mayer survival curve
(log rank p <0.042) (Fig. 1). On the contrary, only nine patients,
seven in the ACLF and two in the non-ACLF group, had low FT4
levels (p = 0.09). Low FT4 levels were not related to outcome.
It is not the ﬁrst time that the sick euthyroid syndrome has
been related to the prognosis of liver cirrhosis. In the past, low
levels of the T4 variant in the sick euthyroid syndrome were
demonstrated to be a good predictor of decreased survival in liver
cirrhosis and T4 levels were inversely correlated with the CTP
score [6]. In addition, low FT3 levels were considered as indicators
of poor prognosis in cirrhotics with non alcoholic liver disease
[5]. However, the prognostic signiﬁcance of low T3 levels in
the sick euthyroid syndrome have not been evaluated so far in
the ACLF setting.
In conclusion, free T3 levels are inversely correlated with the
severity of liver disease and are signiﬁcantly lower in patients
with decompensated cirrhosis who developed ACLF. Sick
euthyroid syndrome with low FT3 levels was related to early
mortality in patients with ACLF.
1.0
0.8
0.6
0.4
0.2
0.0
0 10 20 30 40
Days
C
um
ul
at
iv
e 
su
rv
iv
al
Normal FT3
Log-rank, p = 0.042
Low FT3
Fig. 1. Probability of survival in patients with low compared to normal FT3 in
ACLF group.To the Editor:
We read with interest the article by Maiwall et al. in which serum
ferritin along with hepatic encephalopathy, leukocyte count,
acute-on-chronic liver failure (ACLF) grades and CTP score predict
early mortality in patients with decompensated cirrhosis (DC)
[1]. ACLF has recently been recognized as a speciﬁc clinical form
of liver failure with short term mortality [2,3]. Thyroid test
abnormalities in ACLF and their association with survival have
not been determined so far.
The plasma thyroid hormone proﬁle in patients with cirrhosis
resembles the low T3 or ‘‘sick euthyroid’’ syndrome, common in
many sick patients and normal subjects with caloric deprivation
[4,5]. Thus, a low T3 state in cirrhosis may reﬂect impairment of
hepatic uptake and conversion of T4 to T3 due to diminished
hepatocellular function or to reduced caloric intake. It may be
considered as an adaptive hypothyroid state, which is important
for preserving body protein stores [6]. We aimed to better
understand the thyroid test abnormalities in patients with (DC)
and ACLF compared to those without ACLF.
128 patients (91 [71.1%] males, median age of 61 [interquar-
tile range 53–69] years) with DC were followed for a median of
91 (44–110) days. ACLF was diagnosed in 65 (50.8%) patients
according to the CLIFF consortium criteria [2]. No patient had
signs or symptoms of thyroid disease. Levels of free T3 (FT3)
and free T4 (FT4) correlated inversely with the severity of liver
disease as expressed by the MELD-Na score (r = 0.482 and
0.346, respectively, p <0.001). On the contrary, there was no
correlation of the thyroid-stimulating hormone (TSH) with the
MELD-Na score.
Patients with ACLF compared to those without had signiﬁ-
cantly lower FT3 (1.54 [1.18–1.88] vs. 2.00 [1.55–2.46],
p <0.001) and FT4 levels (1.00 [0.83–1.19] vs. 1.14 [1.00–1.24],
respectively, [p = 0.005]). TSH did not differ between the two
groups. 42 (65%) and 18 (29%) patients had low FT3 levels in
the ACLF and non-ACLF group, respectively (p <0.001). Patients
with low FT3 compared to those with normal FT3 had signiﬁ-6 Journal of Hepatology 2014 vol. 61 j 1438–1452
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Reply to: ‘‘Low free T3 levels are related to early mortality in patients
with decompensated cirrhosis and acute-on chronic liver failure’’
To the Editor:
We would like to thank Agiasotelli et al. for taking a keen interest
in our recently published manuscript where we showed that
serum ferritin is a predictor of early mortality in patients with
decompensated cirrhosis [1]. Agiasotelli and colleagues demon-
strate that low T3 levels in patients with ACLF are associated with
an increased mortality. We would like to clarify that our patient
population was comprised of decompensated cirrhosis and not
ACLF patients. Further, we did not use the CLIF deﬁnition for
the diagnosis of ACLF [2,3].
We have looked into our cohort of patients with decompen-
sated cirrhosis (n = 318, 257 males) and patients with ACLF
(n = 148, 109 males), deﬁned according to the APASL criteria [2]
for abnormalities in thyroid function and their relationship to
predictors of mortality [1]. Median (IQR) free T3, free T4, and TSH
concentration were 2.3 (1.98–2.69) pg/ml, 1.04 (0.9–1.23) ng/L,
and 2.47 (1.28–4.27) lIU/ml, respectively in the decompensated
cirrhotic group. A signiﬁcant inverse correlation of T3 was noted
with predictors of early mortality i.e. the MELD (p = 0.0004,
0.36) and CTP score (p <0.00001, 0.43), hepatic encephalopa-
thy (p <0.0001, 0.46) and leucocyte counts (p = 0.002, 30).
Interestingly, low T3 levels also correlated with an increase in fer-
ritin (p = 0.007, 0.27). Similar to the observation by Agiasotelli
et al., low T3 was associated with decreased survival (log rank
p = 0.0003), whichwas not observed for T4 (p = 0.5) and TSH levels
(p = 0.6) (Fig. 1 A–C). On multivariate analysis, however, low T3
was not a signiﬁcant predictor of mortality in our cohort.
On the contrary, median (IQR) free T3, free T4, and TSH
concentration in patients with ACLF [2] were much lower as com-
pared to patients with decompensated cirrhosis i.e. 1.9 (1.6–2.2;
p <0.0001) pg/ml, 0.96 (0.73–1.12; p = 0.001) ng/L, and 2.1
(0.65–3.5; p = 0.01) lIU/ml, respectively. Low free T3 was noted
in 89% vs. 64% (p <0.0001), low T4 in 16% vs. 4% (p <0.0001) and
low TSH was noted in 18% vs. 3.5% (p <0.0001) of patients with
ACLF, as compared to patients with decompensated cirrhosis,
respectively. Interestingly, serum ferritin showed an inverse cor-
relation with both free T3 (r 0.18, p = 0.012) and TSH (r 0.234,
p = 0.03). Also, in these patients, a signiﬁcantly lower survival
was noted with low T3 (log rank p = 0.005), low T4 (p = 0.014)
as well as low TSH (p = 0.001) (Fig. 1D–F). This could be possible
because within the ﬁrst few hours of the critical illness, T3 con-
centrations decrease due to decreased peripheral deiodination,
while T4 and TSH concentrations may increase or remain normal.
However, if the illness becomes more protracted or severe, a
decrease in the concentration of T3, T4, and TSH is caused by a
decrease in TRH-release from the hypothalamus [4]. Our patients
with ACLF, diagnosed as per APASL deﬁnition, have characteristi-
cally an acute liver failure–like presentation (not just acute
decompensation) on a background of underlying chronic liver
disease with a sudden and massive loss of functional hepatocytes
and activation of the systemic inﬂammatory response syndrome
that probably puts extra stress on the thyroid [2]. In our cohort,
we also found patients with hepatorenal syndrome (HRS) with
signiﬁcantly lower free T3 as compared to those with no HRS
(2.19 ± 0.47 vs. 2.42 ± 0.62; p = 0.04). This is because the 50-mon-
odeiodinases, which produce T3, the biologically active hormone,
are also present in the kidney apart from the liver. Thus, our data
suggest that low T3 levels are frequent in patients with advanced
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